Journals / Türk Psikiyatri Dergisi / 2020 / Cilt: 31 - Sayı: 4

Ten-Year Risk of Cardiovascular Disease in Patients with Bipolar Disorder

Bipolar Bozukluk Tanılı Hastalarda 10 Yıllık Kardiyovasküler Hastalık Riski

Pages
225–231
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is important to identify patients diagnosed with bipolar disorder with a high risk of developing CVD to review the psychiatric treatment and to encourage the patients for preventive approaches.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Patients with bipolar disorder (BPD) are less likely to seek treatment for cardiovascular diseases (CVD) despite the two fold increased CVD-related death rate in BPD.
📊
Key Findings & Data:The aim of this study was to evaluate the relationship between clinical variables, exercise characteristics and 10-year risk of CVD in patients with bipolar I disorder (BPD-I).
💡
Conclusion & Impact:It is important to identify patients diagnosed with bipolar disorder with a high risk of developing CVD to review the psychiatric treatment and to encourage the patients for preventive approaches.
🔬Design:Survey & Empirical Study
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Patients with bipolar disorder (BPD) are less likely to seek treatment for cardiovascular diseases (CVD) despite the two fold increased CVD-related death rate in BPD. The aim of this study was to evaluate the relationship between clinical variables, exercise characteristics and 10-year risk of CVD in patients with bipolar I disorder (BPD-I). Method: The study was carried out with 106 euthymic BPD-I patients who were followed up at the Mood Disorders Centers of Bakırköy Hospital for Mental and Neurological Diseases and Selcuk University Faculty of Medicine. The physical activity status of the patients were evaluated with the Godin Leisure-Time Exercise Questionnaire (GLTEQ) and the prospective 10-year risk of CVD was assessed by the QRISK®2-2017 - CVD risk algorithm. Results: Mean age of the patients were 39.5±8.6 years. The mean QRISK2 score of the patients was 3.64±0.46 %, which did not differ with respect to the gender. Patients’ mean healthy heart age (QAGE) was 8.49±6.46 years ahead of their current age. There was a weak negative correlation between GLTEQ total score and QRISK2 score (r= 0.168), but this was not statistically significant. However, statistically significant positive correlations were determined between the categorical QRISK2 score and the disease age of onset (RR:1.18; 95%CI:1.09-1.28), treatment duration (RR:1.16; 95%CI:1.05-1.29) and the inclusion of atypical antipsychotic agents in the treatment received (RR:5.99; 95%CI:1.12-31.90). Conclusion: A strong positive correlation was determined in this study between the QRISK2 score and the use of atypical antipsychotic drugs in the treatment of the BPD-I patients. It is important to identify patients diagnosed with bipolar disorder with a high risk of developing CVD to review the psychiatric treatment and to encourage the patients for preventive approaches.

Özet

Amaç: Bipolar bozuklukta (BB) kardiyovasküler hastalıklara (KVH)bağlı ölüm oranı genel popülasyona göre iki kat yüksek olduğu hâlde,hastaların KVH için tedavi başvuruları düşüktür. Bu çalışmada bipolarbozukluk tip-I tanılı hastaların klinik değişkenleri ve egzersiz özellikleriyle10 yıllık KVH riski ilişkisini değerlendirmek amaçlanmıştır.Yöntem: Araştırma Bakırköy Ruh ve Sinir Hastalıkları Hastanesi veSelçuk Üniversitesi Tıp Fakültesi Duygudurum Merkezlerinden takipedilen 106 ötimik bipolar bozukluk tip-I hastası ile yürütülmüştür.Hastaların fiziksel etkinlikleri Godin Boş Zaman Egzersiz Anketi ile 10yıllık KVH riskleri ise QRISK®2-2017 algoritması ile değerlendirilmiştir.Bulgular: Yaş ortalaması 39,5±8,6 yıl olan hastaların QRISK2 puanortalaması %3,64±0,46 olarak bulundu. Cinsiyete göre hastalarınQRISK2 puan ortalaması arasında fark saptanmadı. Hastaların sağlıklıkalp yaşı (QAGE) ortalaması şu anki yaşlarının ortalamasından8,49±6,46 yıl daha ileride bulundu. Godin egzersiz anketi toplampuanı ile QRISK2 puanları arasında düşük ve negatif yönde bir ilişkivardı (r=-0,168) fakat istatistiksel olarak anlamlı bulunmadı. Hastalıkbaşlangıç yaşı (RR:1,18; %95GA:1,09-1,28), tedavi süresi (RR:1,16;%95GA:1,05-1,29) ve tedavide atipik antipsikotik olması (RR:5,99;%95GA:1,12-31,90) ile kategorik QRISK2 puan derecelendirilmesiarasında pozitif yönde ve anlamlı düzeyde ilişki bulunmuştur.Sonuç: Bu çalışmada BB tanılı hastaların tedavisinde atipik antipsikotikolması ile QRISK2 arasında kuvvetli bir ilişki bulunmuştur. KVHgelişme riski yüksek olan BB tanılı hastaların belirlenmesi; bu hastalarıntedavilerinin gözden geçirilmesi ve koruyucu yaklaşımlar için teşvikedilmesi KVH’ya bağlı mortaliteyi azaltmak için önemlidir.

🔖

Cite This Article

İNCE, B., ALTINBAŞ, K. (2020). Ten-Year Risk of Cardiovascular Disease in Patients with Bipolar Disorder. Türk Psikiyatri Dergisi, Cilt: 31 - Sayı: 4, 225–231. https://ajindex.com/articles/357388

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Akdemir A, Örsel S, Dağ İ ve ark. (1996) Hamilton depresyon derecelendirme ölçeği (HDDÖ)’nin geçerliği, güvenirliği ve klinikte kullanımı. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 3P 4:251-9.
  2. Amireault S, Godin G (2015) The Godin-Shephard leisure-time physical activity questionnaire: validity evidence supporting its use for classifying healthy adults into active and insufficiently active categories. Percept Mot Skills 120:604-22.
  3. Anderson KM, Odell PM, Wilson PW ve ark. (1991) Cardiovascular disease risk profiles. Am Heart J 121:293-8.
  4. Ballon JS, Pajvani U, Freyberg Z ve ark. (2014) Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab 25:593–600.
  5. Baptista T, Serrano A, Uzcátegui E ve ark. (2011) The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, firstdegree relatives and the general population in Venezuela. Schizophr Res 126:93-102.
  6. Catapano AL, Graham I, De Backer G ve ark. (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 37:2999-3058.
  7. Collins GS, Altman DG (2012) Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2. BMJ 344:e4181. Correll CU, Detraux J, De Lepeleire J ve ark. (2015) Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 14:119–36.
  8. Correll CU, Frederickson AM, Kane JM ve ark. (2008) Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 10:788–97.
  9. Damegunta SR, Gundugurti PR (2017) A Cross-sectional Study to Estimate Cardiovascular Risk Factors in Patients with Bipolar Disorder. Indian J Psychol Med. 39:634–40.
  10. De Hert M, Correll CU, Bobes J ve ark. (2011) Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10:52–77.
  11. Demir NÖ, Tuğlu C (2020) Bipolar bozukluk hastalarında metabolik sendrom ve dürtüsellik ilişkisi. Anadolu Psikiyatri Derg 21:277-84.
  12. Drancourt N, Etain B, Lajnef M ve ark. (2013) Duration of untreated bipolar disorder: missed opportunities on the long road to optimal treatment. Acta Psychiatr Scand 127:136-44. Fa